Showing results (31-40 of 72) with videos related to
Sort By:
Pageof 8
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.The British Journal of Dermatology|February 8, 2019
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitisG Yosipovitch, M Reaney, V Mastey, et al.The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.Acta Dermato-Venereologica|May 18, 2019
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity IndexLieneke F M Ariëns, Abhijit Gadkari, Harmieke van Os-Medendorp, et al.The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.Journal of Asthma and Allergy|December 28, 2020
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung FunctionIan D Pavord, Salman Siddiqui, Alberto Papi, et al.Pageof 8